The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun
Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease (RMD) patients, based on the efforts of the North American Task force.
Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to review on this week's podcast.
According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.
UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, and inflammatory bowel disease, have an augmented risk of cardiovascular (CV) outcomes with
Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.
Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens. EULAR has commissioned a task force
Editor's note: This article originally appeared May 14, 2020, and is being shared again as part of RheumNow's "Best of 2020".
Links:
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
